Outsourcing: Analysis and developments of contract service providers to the pharmaceutical and biotechnology industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing
Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.

Health Systems Raise the Bar on Reimbursing New Drugs

July 2, 2014

Pharmaceutical Technology

As payers refuse to cover new drugs, CMOs take a hit.

Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts

June 29, 2014
PTSM: Pharmaceutical Technology Sourcing and Management

PharmSource special report shows demand for cytotoxic injectable drugs could tap existing CMO capacity.

Outsourcing No Longer Just for Cost-Cutting

June 2, 2014

Pharmaceutical Technology

With budgets growing, clients see CMOs' costs as less crucial.

India's Developing Market Offers Opportunities

May 2, 2014

Pharmaceutical Technology

Biopharma companies should not overlook India's growing market.

Stuck in Neutral

May 2, 2014

Pharmaceutical Technology

The CMO industry's value proposition is limiting its market penetration.

Biopharma Outsourcing Activities Update

April 2, 2014

Pharmaceutical Technology

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Drug Discovery Partnerships between UK CROs and the Swiss Pharma Sector

April 2, 2014

Pharmaceutical Technology

The international pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery.

Under New Ownership

March 2, 2014

Pharmaceutical Technology

Changes in company ownership shake up the CMO industry.

What is Quality by Design (QbD) – and Why Should You Care?

February 26, 2014

Is your development or manufacturing operation experiencing cost over-runs and unproductive delays? Do you want to optimize your development dollars and ensure a robust commercial process? You are not alone.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here